Objective To evaluate whether targeted sequencing and relative mutation dosage can be used to diagnose correctly inheritance of maternal b-thalassaemia mutations in cell-free DNA.
Introduction b-Thalassaemia is one of the most common monogenic diseases worldwide, resulting from HBB gene mutations, reducing or abolishing synthesis of the b-globin chains of the haemoglobin tetramer. 1 Inheritance is autosomal recessive, and therefore each pregnancy has a 25% risk for b-thalassaemia major. Causing profound anaemia if not treated with regular blood transfusions, b-thalassaemia can lead to death in childhood. Nearly 300 b-thalassaemiacausing variants have been identified; 2 fortunately, mutations tend to cluster within geographical regions, simplifying assay design for defined populations. 3 Approximately 65% of b-thalassaemia cases in South East Asia and Li Xiong and (IVS-II-654C>T). 4 The haemoglobin E mutation (HBB: c.79G>A; HbE) is also prevalent. 5 Invasive prenatal diagnosis (IPD) for pregnancies at risk of a haemoglobinopathy can be offered, but due to a procedure-related risk of miscarriage of 0.1-0.2%, 6 non-invasive prenatal diagnosis (NIPD) without risk of pregnancy loss is preferable. Following the discovery of cell-free fetal DNA (cffDNA) in maternal plasma, 7 many studies have been conducted using this source of genetic material to develop NIPD for b-thalassaemia. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Most focus on detecting inheritance of paternal mutations when parents carry different mutations. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] The paternal mutation will only be present in the maternal circulation if it has been inherited by the fetus, raising two possibilities: either the baby has inherited only the paternal mutation (in which case will be a carrier) or he/she has inherited mutations from both parents (and will be affected). Using paternal exclusion, it is not possible to discriminate between these two scenarios, requiring the mother to undergo IPD to confirm the genotype. cffDNA constitutes 10-15% of the cell-free DNA (cfDNA) 18 and it is difficult to discriminate fetal from maternal alleles. Maternally inherited b-thalassaemia mutations have been detected using whole genome sequencing 19 and relative haplotype dosage (RHDO); 20 both approaches are currently prohibitively expensive for clinical implementation. Relative mutation dosage (RMD) using digital polymerase chain reaction (PCR) was explored for assessing fetal inheritance of autosomal recessive disorders [21] [22] [23] but was also initially limited by cost concerns.
Our aim was to determine whether the fetus had inherited maternal mutations in addition to a paternal mutation. We targeted five HBB mutations, using a novel RMD algorithm to detect allelic imbalance between maternal mutant and wild-type alleles in cfDNA. Combining our maternal exclusion test with paternal exclusion could result in a 75% reduction in IPD for pregnancies in couples carrying different mutations for an autosomal recessive disorder.
Methods

Patient recruitment and sample collection
Samples were collected for a previously published study from carrier couples at risk of having a child affected with b-thalassaemia, 13 with the approval of the Institutional Review Board for Nanfang Hospital (study number NFEC-2014-048). All couples gave written informed consent. A 10-ml aliquot of maternal blood was collected into K 3 
cfDNA extraction
Fetal inheritance of a paternal mutation was demonstrated in 50 cases (including two false-positive cases), 13 which were classified as 'paternal mutation positive' in this study. Plasma was available for 49 of these cases, and cfDNA was extracted from 3 ml plasma using the QiaAmp Circulating Nucleic Acid kit (Qiagen), followed by elution into 75 ll of elution buffer AVE.
Design of nested-PCR primers for detection of maternal mutations
Maternal mutations were targeted using nested-PCR. We examined the following: HBB:c.-78A>G (-28A>G), HBB: c.52A>T (CD17A>T), HBB:c.126_129delCTTT [CD41/42 (-TCTT)], HBB:c.316-197C>T (IVS-II-654C>T) and HBB: c.79G>A (HbE). The HbE and the CD17A>T mutations are located very close together on the HBB gene and so a single primer pair was used to amplify both mutations. Sequences for the first round of nested-PCR are detailed in Table S1 ; the primers for the second round of PCR have been published previously. 13 For the second round of PCR, forward primers contained the Illumina P5 adaptors and a 6-bp index barcode, and reverse primers contained a P7 primer sequence. We used three pairs of overlapping primers for each mutation, indicated in results tables as P1, P2, and P3.
Library preparation for thalassaemia mutations
The first round of PCR was carried out using 15 ll of cfDNA, 1 x ImmoBuffer (Bioline), 3.2 mM dNTP mix, 4 mM MgCl 2 , 400 nM forward and reverse primers, and 2.5 U IMMOLASE DNA Polymerase (Bioline, UK), in a final volume of 25 ll. Thermal cycling conditions were as follows: 10 minutes at 95°C, followed by 15 cycles of 95°C for 30 seconds, 60°C for 30 seconds, and 72°C for 30 s, with a 7-minute extension at the end. The second round of PCR was carried out using 6.5 ll of PCR product from the previous round of PCR, 1 x ImmoBuffer (Bioline), 2.5 mM dNTP mix, 3.8 mM MgCl 2 , 500 mM forward and reverse primers, and 1 U IMMOLASE DNA Polymerase in a final volume of 20 ll. Thermal cycling conditions were as follows: 10 minutes at 95°C, followed by 14 cycles of 95°C for 30 seconds, 60°C for 30 seconds, and 72°C for 30 seconds. Amplicons were purified using Isolate II PCR clean-up columns (Bioline) and eluted into 20 ll of elution buffer, then quantified using a Qubit Fluorometer (Invitrogen).
Purified PCR products were diluted to 4 nM in Elution Buffer (Qiagen) and equal amounts from up to 24 patients were pooled to yield a single 4 nM library.
Measurement of fetal fraction (FF)
A panel targeting 35 biallelic insertion/deletion polymorphisms was used to measure FF. 24 PCRs were carried out using 12.5 ll of 29 Quantifast Multiplex PCR Mix (Qiagen), 200 nM each primer, and 4.5 ll plasma DNA or gDNA (1 ng/ll), in a final volume of 25 ll. Cycling conditions were as follows: 10 minutes at 95°C, then 25 cycles of 30 seconds at 95°C, 90 seconds at 60°C and 90 seconds at 72°C with a final extension of 72°C for 10 minutes. Libraries were prepared using TruSeq Nano DNA Sample Preparation kits (Illumina) with indexed adaptors diluted 1:100. Up to 24 samples per run were diluted to 4 nM, pooled, and sequenced as described below.
Sequencing using the Illumina MiSeq
Libraries were denatured using sodium hydroxide and the library then diluted to a final concentration of 16 pM. This library was mixed with a PhiX control to give a 5% PhiX spike, providing sequence diversity. Cluster generation was carried out onboard the MiSeq followed by initiation of a single-end 100 cycle sequencing protocol.
Data analysis
The fetal fraction was calculated for all samples using an indel panel. 24 Briefly, Fastq files were analysed using a Python script to count forward and reverse reads generated for each allele. The fetal fraction for each indel was calculated as follows:
The mean FF given all informative indels for each sample was used as an estimate of the FF. Indels yielding a FF greater than 50% and lower than 1.5% were excluded from analysis.
For assessing whether there was a statistically significant difference between the counts of mutant and wildtype alleles in a plasma sample, we used a modified sequential probability ratio test (SPRT) algorithm. 22 A pair of SPRT curves are constructed based on the expected ratio of the mutant and wildtype alleles for simultaneous testing of the null and alternative hypotheses as data accumulated. The null hypothesis was that the dosage of the mutant and wild-type alleles was balanced (i.e. both the mother and fetus were heterozygous). The alternative hypothesis was that the alleles were unbalanced (i.e. a heterozygous mother carrying a homozygous fetus). If the null hypothesis is correct, the expected ratio (R) between the maternal mutation and wild-type allele would be 0.5. If the alternative hypothesis is correct and the fetus is homozygous for the mutation, the expected ratio (R) would be (1 -f)/2, where f represents the fetal DNA fraction given that the father and mother carried two different mutations.
The lower and upper boundary curves were constructed based on the expected ratio (R) and an odds ratio of 8 to serve as the threshold for accepting the null and hypotheses, respectively. If the observed ratio between the mutant and wild-type alleles exceeded the upper boundary curve, the alternative hypothesis would be accepted, indicating the fetus was homozygous for the over-represented allele (either the mutant or the wild-type).
The upper and lower boundaries for SPRT classification are calculated as follows:
, h 0 = proportion of plasma DNA molecules carrying the maternal mutations allele if the fetus has inherited the maternal wildtype allele, = (1 -f)/72, h 1 = proportion of plasma DNA molecules carrying the maternal mutations allele if the fetus has inherited the maternal mutation, = 0.5, N = number of plasma DNA molecules covering the locus of interest.
Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) calculations were performed using MEDCALC for Windows, version 15.0 (MedCalc Software, Ostend, Belgium). All values are given followed by the 95% confidence interval in brackets.
Results
Detection of maternal mutations in cases which were true paternal mutation-positive Forty-seven of the 49 cases examined were true-positives for inheritance of the paternal mutation. A modified version of SPRT was used to determine fetal genotype with respect to inheritance of the maternal mutation. Summary data are presented in Table 1 , and read counts for each allele are given in Table S2 . Using our method, 46 of 47 samples which were true-positives for inheritance of the paternal mutation received a classification (97.8%), one sample being inconclusive. Twenty-three of 46 samples were correctly classified as inheriting the wild-type maternal allele (50.0%) and 19 were correctly classified as having inherited the mutant maternal allele (41.3%). Overall, this gave us a diagnostic accuracy of 91.3% with respect to the maternal allele when the paternal mutation had been correctly classified as inherited. In cases where the paternal inheritance has been correctly classified, our sensitivity is 86.4% (65.1-97.1%) and specificity 95.8% (78.9-99.9%). Table 1 . Relative mutation dosage classification for fetal inheritance of the maternal mutation for fetuses that were previously found to have inherited the paternal mutation. Two samples were false-positives for inheritance of the paternal mutation Pat Mut 
U
We obtained one false-positive (FP) and three false-negatives (FN). The FP case was CD41/42(-TTCT)-positive using all three amplicons, and had an FF of 7.9%. Two FNs for IVS-II-654C>T mutation were incorrect for two of three amplicons; the third FN (-28A>G) was incorrect using all three amplicons. The FFs for all three were above 7.7%. To confirm that the maternal allele should have been inherited in all three of these negative cases, and to ensure that our primers were able to detect the maternal and wild-type alleles equally, we sequenced the gDNA from amniotic fluid or a fetal blood sample using nested-PCR. In all three cases, the fetus had inherited the maternal mutation, showing approximately equal numbers of reads for wild-type and mutant alleles ( Figure S1 ). The PPV for final classification of these 46 samples was 95.0% (73.5-99.2%) and the NPV 88.5% (72.8-95.7%).
Detection of maternal mutations in cases which were false-positives for inheritance of the paternal mutation
Two of the cases tested for the presence of the maternal mutation were FPs for inheritance of the paternal mutation. As in fact these samples have not inherited the paternal mutation, they are carriers at worst, and do not require any further testing; however, in a sequential testing scenario, these FPs would be carried forward to stage two of the procedure for testing for the maternal mutation. Therefore, we proceeded with the analysis. In both cases we correctly detected the inheritance of the maternal mutations [one case of CD41/42(-TTCT) and one case of -28(A>G)]. This result of 'maternal mutation positive' occurs whether we set the SPRT calculation to 'paternal mutation inherited' or 'paternal mutation not inherited'. The consequence of the false-positive for the paternal allele is that the two fetuses are given an overall classification of affected, when in fact they are carriers. Including these two samples in our overall cohort of samples with a positive classification for the paternal mutation, we have a correct classification for inheritance of the maternal allele in 44/48 (91.7%) of cases: sensitivity 87.5% (95% CI 67.6-97.3%) and specificity 95.8% (95% CI 78.9-99.9%), PPV 95.5% (95% CI 75.4-99.3%) and NPV 88.5% (72.6-95.7%).
Overall diagnostic accuracy of our sequential test for fetal genotype
The samples that we tested in this study were from an initial study cohort of 83 cases, 33 of which were found to be paternal mutation-negative. 13 Including these samples, we can calculate our overall diagnostic accuracy for discriminating 'affected' and 'unaffected' fetuses using our sequential testing protocol. One had insufficient plasma for further testing and one was inconclusive for inheritance of the maternal allele due to a lack of cfDNA available for testing of the third 
Discussion
Main findings
We used nested-PCR with three internal overlapping amplicons to target four common South East Asian b-thalassaemia mutations, and HbE, followed by RMD to classify inheritance of maternal alleles. Results were concordant with invasive testing in 44/48 (91.7%) of cases. We achieved a sensitivity of 87.5% (67.6-97.3%) and a specificity of 95.8% (78.9-99.9%), suggesting that our rapid, cost-effective, sequential RMD strategy has potential clinical utility.
Including results for detection of paternal alleles, we achieved concordance of 92.6% for classification of a fetus as 'affected' or 'unaffected'. Three fetuses were incorrectly classified as 'affected', two of which were FPs for inheritance of the paternal allele. We recommend an invasive test to confirm a positive result, and so, although undesirable, it is possible to deal with FPs clinically. The three FN results are more problematic, as there would be no confirmation.
Strengths and limitations
This is one of the largest feasibility studies of screening for monogenic disorders using cfDNA, and certainly the largest aimed at diagnosing both parent's alleles for b-thalassaemia. Most studies have focused on exclusion of inheritance of paternal mutations. A recent meta-analysis by Zafari et al. 25 describing detection of paternal b-thalassaemia mutations noted an overall sensitivity of 99%. However, there have been few studies concerning detection of the maternal mutation. Recent work has demonstrated successful use of RHDO for detection of inheritance of maternal mutations. [26] [27] [28] [29] [30] RHDO has been implemented successfully into some clinical laboratories, but generally remains prohibitively expensive. 26 Importantly, most of RHDO requires a proband for haplotyping, meaning the test would not be available to a couple during their first pregnancy. Hui et al. described a method for RHDO in the absence of a proband, 28 but it is currently too expensive for implementation. Our RMD approach also shows promise for detection of inheritance of maternal mutations, and can be used without a proband. The assay relies solely on PCR reactions for amplification of target regions and library preparation; therefore, the cost per test is minimal. The indel libraries for quantification of FF were prepared using commercial kits, adding significantly to the test cost. However, it would be possible to redesign the panel to incorporate adapters plus sample-specific indexes using a two-step PCR protocol, making the entire procedure PCRbased, further reducing costs.
The test covers around 65% of pregnancies at risk of b-thalassaemia regionally. Incorporating additional amplicons to cover other variants will be straightforward and we anticipate no difficulties in testing for any point mutation or small deletion/duplication. In this study, we examined pregnancies where the parents carry different mutations; when parents carry the same mutations, we could employ the same PCR-based approach to amplify the appropriate region, using a previously published SPRT algorithm 22 to classify inheritance of the mutation. Samples from couples with the same or different mutations can be multiplexed, as analysis is performed after completion of sequencing.
The methodology described here is similar to that used in our previous study on paternal mutation detection, 13 but we found that nested-PCR for maternal mutation detection was more sensitive, reducing the possibility of non-specific mispriming. The modified RMD algorithm is key to the success of our test, and confers novelty to the study.
One major limitation was the three FN results; until this issue is resolved, the test cannot be clinically implemented. Using a classification strategy where a mutation-positive call for any of the three amplicons implies 'mutated' improves the sensitivity of the test in the cohort of 49 samples where the paternal mutation was inherited. The number of falsenegatives would be reduced to one, we would correctly classify the 'inconclusive' sample, but gain two false-positives. This would translate to a sensitivity of 96.0% (79.7-99.9%), a specificity of 87.5% (67.6-97.3%), a PPV of 88.9% (73.5-95.9%) and an NPV of 95.5% (75.4-99.3%).
Another limitation was fact that 41 samples were collected during the second and third trimesters of pregnancy and so would be expected to have a higher FF. 31 It is preferable to perform prenatal testing during the first trimester of pregnancy. It will be essential for us to collect additional samples at earlier gestations to demonstrate we can routinely achieve accurate results in the first trimester. This will allow us to define the minimum FF threshold for accepting a sample for NIPT using RMD.
Interpretation
Our diagnostic accuracy of 92.6% is comparable to NIPT for monogenic diseases reported in other studies; 32 however, RHDO shows higher levels of concordance, 26, 28, 30 so our test still needs improvement. We obtained three FN results and further work will be required to reduce these. The percentage of cffDNA for these samples ranged from 7.7 to 13.5%, so misclassification did not result from insufficient FF. We considered allele dropout as the cause of the FNs; sequencing of fetal gDNA for all three samples indicated equal quantities of wild-type and mutant allele, ruling out SNPs under the primers leading to allele dropout. Nested-PCR on samples with a particularly low initial abundance of cfDNA may skew amplification efficiency of one allele, 33 resulting in an incorrect RMD classification, despite samples having an acceptable FF. This appears to have been the case in the FP sample b85 where counts for the maternal mutation are over-represented to a level higher than theoretically possible using all three amplicons. The solution may be to reduce the number of cycles of PCR, thus reducing any bias introduced.
Two of our FPs were caused by FP calls for inheritance of the paternal mutation, with correct classification of inheritance of the maternal allele. The percentage of paternal mutation for each replicate was significantly lower than the overall FF estimate (b115: paternal mutations 1.7, 0.8, 1.5, FF 11.3%; b66: paternal mutations 3.7, 1.2, 1.8, FF 16.1%). In a clinical scenario, this would raise suspicion, requiring repeat testing. It is rare to obtain an FP for the paternal allele assuming no sample contamination. One sample was unclassified as two overlapping amplicons provided different results and there was not enough of the sample to repeat using the third amplicon. A second blood collection would be required to enable repeat testing.
Although accuracy of IPD is superior to NIPT using cffDNA, several studies have shown that many women would decline an invasive test for single gene disorders such as sickle cell disease 34 or cystic fibrosis 35 due to increased risk of miscarriage. These women may be more willing to take a non-invasive test, enabling them to make decision about the continuation of their pregnancy in the case of an affected fetus, or giving them the opportunity to prepare psychologically and physically for the birth of an affected child if they choose to continue their pregnancy. 36 
Conclusion
This study demonstrates that it is feasible to test non-invasively for maternal b-thalassaemia mutations targeting known variants on the HBB gene followed by RMD. Optimisation of PCR conditions, as well as careful setting of the thresholds for calling a true-positive for the paternal mutations should increase accuracy. A prospective blinded clinical study will be required to assess the performance fully. It will be relatively simple to add in primer pairs for other less prevalent mutations, and to multiplex with samples being tested for other single gene disorders in the same sequencing run. Our data suggest that our sequential testing strategy has feasibility for development into a clinical test.
Disclosure of interests
None declared. Completed disclosure of interests form available to view online as supporting information.
Contribution to authorship
XL, ANB, RH, SSYH, ZM and MC designed the experiments. XL and ANB carried out the experiments. XL, ANB, LJ, KCAC and MC wrote the manuscript. LJ, ZM and MC conceived and supervised the project. KCAC designed the SPRT algorithm for data analysis. All authors provided critical comments and editorial changes.
Details of ethics approval
Samples were collected with the approval of the Institutional Review Board for Nanfang Hospital (study number NFEC-2014-048, date of approval 18 June 2014). The study was carried out in Singapore with approval from the National Healthcare Group Domain Specific Review Board, Singapore (DSRB2013/00837, date of approval 2 January 2014).
Funding
This work was supported by the National Medical Research Council/Clinician Scientist Award (NMRC/CSA/0059/2014) and the Natural Science Foundation of Guangdong Province (1414050001657). The funding body played no part in the study design, data collection, data analysis or manuscript preparation. Figure S1 . Number of reads for wild-type (Wt) and mutant alleles (Mut) in fetal genomic DNA for the three false-negative samples. The site of the mutation is indicated below the sample numbers. In all three cases, the mutant allele was inherited from the mother. The wild-type allele at each mutation site was inherited from the father. Table S1 . Sequences of the primers used for the first round of nested-PCR. Table S2 . Counts for wild-type and mutant alleles for all samples previously classified as positive for the presence of the paternal allele. Two samples were false-positives for the paternal mutation. P1, P2, and P3 indicate primer pairs 1, 2, and 3, respectively. Wt, wild-type allele; Mut, mutant allele; U, unclassified. In some cases there was insufficient sample for testing the third amplicon, but we had already achieved two concordant results with the other. &
